Experience
Sell-side Advice
Client
Transaction
Sale of trademark and intellectual property ARTRESANInvestor
Date
2013Capital advisory to the owner of ASA sp. z o.o. in the sale process of the ‘Artresan’ brand – market leader in the joints’ support products category in Poland.
The sale process has been completed of the ‘Artresan’ brand – market leader in the OTC category of formulas that assist in the functioning of joints.
Holon was the exclusive transaction advisor to ASA Sp. z o.o. in the divestment process, whose role included preparation of the investment proposal, management of the tender process and transaction structuring. The parties have decided not to disclose the value of this transaction.
Artresan is a diet supplement used in the protection and maintenance of the correct functioning of the joints. The brand is also the market leader in Poland in the joints’ support category, with a volume share of 17% and with sales value (wholesaler re-sale) of cca. 21 mln PLN in 2012, according to IMS Health Poland.
Are you interested in selling your company or acquiring a company?
For information on how we carry out such projects, please visit our website or contact us directly. The Holon team are available to help with any enquiries you may have. Contact us
Company information
The seller ASA Sp. z o.o. (www.asavita.pl) has in its portfolio such products as: LaciBios femina, Sterolea, MaxiVision Total, Novocardia, Menoplant Soy-a 40+, Hepason Complex, ProUro, Femiferal, as well as specialist pharmaceutical dermocosmetics. The sale of ‘Artresan’ allows ASA Sp. z o.o. inter alia to invest in new innovative formulas, as well as to strengthen the market position of its existing product portfolio.
Investor information
The strategic investor in ‘Artresan’ is USP Zdrowie – leader in the OTC segment of the Polish pharmaceutical sector and owner of such brands as: Ibuprom, Apap, Gripex, Stoperan, Vigor, Verdin, Xenna and others. USP Zdrowie’s portfolio currently includes over 100 products, which for many years have been trusted by both consumers and pharmacists.